Reimbursement

Zitter Health Insights and Specialty Pharmacy Times partner to recognize the top performing specialty pharmacies based on patient satisfaction.

Core services are basic to specialty pharmacy offerings, while enhanced services are only provided with payment from a third party, usually a drug manufacturer.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses the challenge of out-of-pocket spending and the impact on drug adherence.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.

Top articles of the week on Specialty Pharmacy Times.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses challenges balancing the quality of care with the high cost of treatments.

Eric Peacock, co-founder and CEO of MyHealthTeams, how bringing the voice of patients to clinical research can enhance health care.

Daniel P. Kus, BS Pharm, RPh, discusses how the growth of drug prices could impact the specialty pharmacy patient experience.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses how specialty pharmacies can navigate limited distribution networks.

The initial encounter between a patient and a specialty pharmacy is crucial to the long-term success of the partnership.

Top articles of the week on Specialty Pharmacy Times.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses medication management processes that can improve adherence to specialty therapies.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses actions that can enhance the relationship between manufacturers, payers, providers and patients in specialty pharmacy.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Paul LeVine, vice president of Analytic Services at TrialCard, discusses how specialty pharmacies can use patient feedback surveys to improve treatment outcomes.

Pharmacist interventions can help improve medication adherence among patients in predominantly African-American and Hispanic communities.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses the components of an effective patient management program to optimize adherence.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the challenges of access to high cost specialty medications.

Top news of the day from across the healthcare landscape.

Researchers examine how socialization institutes effect the way individuals in low income areas relate to HIV/AIDS after a natural disaster.

The Right to Try Act allows terminally ill patients to take investigational treatments that have passed basic safety testing.

Heart failure-related apps that monitor symptoms fall short of expectations.

Study finds high out-of-pocket costs remain a barrier for initiation of oral cancer drugs.

Specialty pharmacy stakeholders need to focus on measureable near-term processes that could improve speed to therapy.

Access to oral chemotherapies is filled with challenges for providers and patients that can be significant, resulting in delayed therapy.

Misinformation among consumers and the media regarding specialty pharmacies illustrates the importance of leveraging factual information to highlight specialty services for patients to raise the customer service bar even higher.

Conflicting opinions surround drug copay coupons, which can improve out-of-pocket costs while decreasing the effectiveness of cost-sharing requirements that promote prudent prescribing and purchasing choices.

Researchers evaluate patient preferences in the treatment of rheumatoid arthritis.

Out-of-pocket limits significantly higher under ACA bronze and silver plans than with employer-based plans.